Veolia, Bio-Acids to build KSA’s first citric acid plant

Dr. Badr Ghawji, MD of Veolia Water Technologies KSA, and Yassir O. Al-Sebaei, MD of Saudi Bio-acids Company.
Updated 08 September 2018
0

Veolia, Bio-Acids to build KSA’s first citric acid plant

Veolia Water Technologies Saudi Arabia has announced its latest contract with Saudi Bio-Acids Company. Under the agreement, Veolia will design and build full turnkey wastewater treatment plants for a new greenfield factory in Jeddah.

The plants will integrate several of Veolia’s innovative technologies — including the Biothane Advanced EGSB Anaerobic, membrane bioreactor (MBR), as well as tertiary treatments using reverse osmosis technology.

Saudi Bio-Acids Company aims at build the Arab world’s first citric acid production facility. The company is targeting a production output of 80,000 metric tons within two years for three different products — citric acid anhydrous (CCA), citric acid monohydrate (CAM) and trisodium citrate (TSC) — after commencing operations at the plant. Citric acid is used in many industries that range from food and beverages to pharmaceuticals and personal care.

 Currently, most of the demand for citric acid across the Middle East is met with imports from overseas. With this plant, Saudi Arabia will start producing this important component for the food industry in the Kingdom.

Dr. Badr Ghawji, managing director of Veolia Water Technologies Saudi Arabia, said: “Our suite of water and wastewater solutions offers maximum technical advantages for our clients, and we look forward to recommending our anaerobic technologies to more food and beverage manufacturers operating in this region.”


Pharmaceutical giant Allergan to train KSU pharmacy students

Updated 23 April 2019
0

Pharmaceutical giant Allergan to train KSU pharmacy students

Global biopharmaceutical company Allergan has signed a memorandum of understanding (MoU) with King Saud University (KSU) that focuses on developing a robust student-exchange program by facilitating training opportunities for Saudi nationals.

The agreement was signed by Ramsey Morad, Allergan’s vice president for India, Middle East and Africa, and Dr. Aws Al-Shamsan, dean of the College of Pharmacy at the university. The MoU is in line with the Kingdom’s overall efforts to drive more cooperation levels between the public and private sectors, with the underlying objective to integrate Saudi nationals into various fields within the health-care sector.

Under the agreement, Allergan will provide training courses on an annual basis for students at the College of Pharmacy as well as programs to develop their scientific and medical knowledge and align them to international industry best practices. Students will be assessed according to set parameters, and the top performers will earn an internship opportunity with the company

In addition, Allergan will run courses for faculty members at the College of Pharmacy with a focus on leadership skills.

Morad said: “We have used practical methods to express our commitment toward the Kingdom and toward the realization of Vision 2030. We are placing a very high emphasis on developing the local capabilities of Saudi nationals within the health-care sector, and this partnership with a leading university in the region is one of the steps we are taking. Saudi Arabia is at the heart of our operations in the region, and this MoU represents a key milestone in our efforts to attract the young minds of tomorrow and integrate them as core members of our Allergan team.” 

Al-Shamsan said: “We are proud to partner with Allergan to implement internationally recognized knowledge-based programs for the development of our students. With this MoU, we are focusing on the enhancement and development of the pharmaceutical sector across the Kingdom. We are guided by the mission to provide students experiences to learn from international best practices and, at the same time, work toward the improvement of the quality of the pharmaceutical sector in the Kingdom.”

Allergan said it is committed to a wide range of programs with health-care professionals, patients and national entities across the Kingdom. The company’s investments through its joint venture, Allergan Saudi Arabia, include the development of medical training centers focused on training health-care professionals in medical aesthetics.